LONDON and LUGANO, Switzerland, Nov. 18,
2019 /PRNewswire/ -- Accord Healthcare Limited
("Accord") and ADIENNE Pharma & Biotech S.A. ("ADIENNE") have
entered into an exclusive licencing and distribution agreement for
the commercialisation of TEPADINA® (thiotepa) 15mg and 100mg
lyophilized powder for injections.
ADIENNE is also working on a new delivery presentations for
TEPADINA® (thiotepa) and other oncology and cytotoxic drugs to
improve and enhance the healthcare professional and patient
experience.
The new delivery presentations for TEPADINA® will be
commercialized by Accord in Europe
and India.
With this new partnership, Accord secures exclusive rights to
market, commercialise and sell ADIENNE's novel chemotherapy brand
TEPADINA® which will be supported by an expert sales force, and a
seasoned marketing team that has successfully launched multiple
oncology products in Europe. Accord will begin selling
TEPADINA® across select markets in the European region such as
Italy, Spain, UK, Ireland, Benelux and Portugal. Additional markets will be included
in 2020, with the aim of Accord becoming the sole distributor
across all European markets by early 2021.
ADIENNE will continue to be the Marketing Authorization
Holder in the territories and responsible for the manufacture and
supply of the product.
TEPADINA® (thiotepa) is indicated in the conditioning regimens
before autologous and allogeneic haematopoietic stem cell
transplantation to treat haematological diseases and solid tumours
both in adult and paediatric population.
It has been granted Orphan Drug Designations by the EMA and by
US Food and Drug Administration (FDA).
Dr. Antonio Francesco Di Naro,
Founder, Owner and President of ADIENNE, said: "We are very pleased
to have established this collaboration with Accord, whose
established track record of successful marketing of complex
oncology and specialty products gives us confidence that they are
the best partner for our TEPADINA® product. Accord has a
remarkable commercial team and infrastructure in place, and we are
highly confident in their ability to successfully leverage that
platform with us."
James Burt, Executive Vice
President, Europe and MENA of
Accord, said: "We are committed to bringing complex, added value
products to improve the lives of cancer patients. This agreement
builds on our oncology platform adding to our extensive oncology
experience in Europe, where we
supply more than 35 oncology products across the region. We are
excited to take over the commercialisation of this product, which
will provide tangible advantages to patients and healthcare
providers, and we look forward to a mutually beneficial and
successful collaboration with ADIENNE."
About ADIENNE Pharma & Biotech
ADIENNE Pharma & Biotech is a mid-size bio-pharmaceutical
company founded in 2004, dedicated to the treatment of rare and
severe diseases, operating in worldwide pharmaceutical market. The
headquarter is based in Lugano (Switzerland). The company is mainly focused,
from the research to commercialization, on the fields of
onco-haematology, autoimmune diseases, bone marrow and solid organ
transplantation. ADIENNE's product portfolio includes name
patient-based products (NBP) and owned licensed medicinal products.
www.adienne.com
About Accord Healthcare
Headquartered in the United
Kingdom (UK), Accord Healthcare Europe is one of the fastest
growing pharmaceutical companies in Europe. Accord has one of the largest market
footprints of any European generic and biosimilars companies
selling generic medicines in over 80 countries around the
world.
This global footprint enables us to deliver vital, affordable
medicines to national health systems supporting healthcare
professionals to transform patient lives worldwide.
Our approach is agile and inventive, always seeking to improve
our products and patients' access to them. We're driven to think
differently and deliver more for the benefit of patients worldwide.
www.accord-healthcare.com